The US Food and Drug Administration (FDA) has published two new draft guidance documents that will provide clarity to medical product developers on the agency’s recommendations for researching and developing the next generation of individualised therapies.

Called ‘Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease’, the first draft guidance addresses the important topic of finding treatments that address the underlying molecular changes that often cause or contribute to diseases.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The guidance proposes a new approach for drug developers to enrol patients based on the identification of rare mutations into clinical trials for targeted therapies.

It also discusses the evidence that is required to demonstrate effectiveness for various molecular subsets within a particular disease.

This is expected to lead to consistent development and approval of targeted therapies for patients.

“We specifically addressed a more efficient pathway for developing drugs targeted to the rare pediatric disorder Gaucher disease.”

The second draft guidance, ‘Investigational IVD Devices Used in Clinical Investigations of Therapeutic Products’, discusses the way of determining if an in-vitro diagnostic (IVD) device used in a study must undergo its own FDA review.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Once finalised, it is set to clarify the appropriate regulatory pathway for investigational in-vitro diagnostic (IVD) devices used in clinical trials for therapeutic products.

Building on the IVD draft guidance, FDA is also considering methods to streamline the review of oncology therapeutic products and the IVDs used with them.

FDA said in a statement: “These draft guidances are just a few examples of the FDA’s ongoing efforts to advance the development of innovative, targeted drugs and foster the availability of individualised treatment approaches.

“Finally, we specifically addressed a more efficient pathway for developing drugs targeted to the rare pediatric disorder Gaucher disease.”